NASDAQ:CALC CalciMedica Q2 2026 Earnings Report $1.72 -0.03 (-1.44%) As of 11:52 AM Eastern This is a fair market value price provided by Massive. Learn more. ProfileEarnings HistoryForecast CalciMedica EPS ResultsActual EPS-$0.45Consensus EPS -$1.43Beat/MissBeat by +$0.98One Year Ago EPSN/ACalciMedica Revenue ResultsActual RevenueN/AExpected RevenueN/ABeat/MissN/AYoY Revenue GrowthN/ACalciMedica Announcement DetailsQuarterQ2 2026Date8/11/2026TimeBefore Market OpensConference Call DateN/AConference Call TimeN/AUpcoming EarningsCalciMedica's next earnings date is estimated for Wednesday, November 11, 2026, based on past reporting schedules. Conference Call ResourcesEarnings HistoryCompany Profile CalciMedica Earnings HeadlinesCalciMedica consensus price target raised 400% to $38.25September 15, 2026 | msn.comCalciMedica Inc. (NASDAQ:CALC) Receives Average Recommendation of "Hold" from BrokeragesSeptember 14, 2026 | americanbankingnews.comThe REAL Reason Trump is Invading IranFor a moment… Forget about Trump’s ties to Israel. Forget about reports of Iran’s nuclear program. Because my research has led me to believe we’re risking World War 3 with Iran for a completely different reason.September 25 at 1:00 AM | Banyan Hill Publishing (Ad)CalciMedica to Participate in the H.C. Wainwright 28th Annual Global Investment ConferenceSeptember 8, 2026 | markets.businessinsider.comCalciMedica to Participate in the H.C. Wainwright 28th Annual Global Investment ConferenceSeptember 8, 2026 | globenewswire.comCalciMedica, Inc. (CALC) Stock Major Holders - Yahoo FinanceSeptember 2, 2026 | finance.yahoo.comSee More CalciMedica Headlines Get Earnings Announcements in your inboxWant to stay updated on the latest earnings announcements and upcoming reports for companies like CalciMedica? Sign up for Earnings360's daily newsletter to receive timely earnings updates on CalciMedica and other key companies, straight to your email. Email Address About CalciMedicaCalciMedica (NASDAQ:CALC) is a clinical-stage biopharmaceutical company focused on developing therapies for serious inflammatory and immune-mediated diseases. The company’s research is centered on calcium release-activated calcium (CRAC) channels, which help regulate immune-cell activation and inflammatory responses. CalciMedica’s lead investigational product is Auxora, also known as zelnecirnon or CM4620. The selective CRAC channel inhibitor has been evaluated in clinical studies for conditions including acute pancreatitis and associated acute kidney injury, as well as other diseases involving excessive inflammation. Auxora remains an investigational therapy and has not been approved for commercial use. CalciMedica was founded in 2007 and is based in La Jolla, California. The company became publicly traded on the Nasdaq under the symbol CALC following a business combination with Graybug Vision that was completed in 2023. Its clinical development activities have primarily involved studies in the United States, with potential applications for its platform being evaluated across multiple inflammatory disease areas.View CalciMedica ProfileRead more More Earnings Resources from MarketBeat Earnings Tools Today's Earnings Tomorrow's Earnings Next Week's Earnings Upcoming Earnings Calls Earnings Newsletter Earnings Call Transcripts Earnings Beats & Misses Corporate Guidance Earnings Screener Latest Articles Super Micro’s Vera Rubin Shipments Put Its AI Infrastructure Advantage to the TestHims & Hers Slides Nearly 7% as Legal Pressure Adds to Its Growing List of Risks3 Space Stocks to Watch as SpaceX Reshapes the Launch MarketOil May Be Stronger Than It Looks—And Diamondback Is on SaleBlackBerry Shifts Gears With Coretura DealCintas Raises Guidance as a Major Catalyst Moves Closer3 Restaurant Stocks Near 52-Week Lows as Consumer Pressure Builds Upcoming Earnings Micron Technology (9/30/2026)NIKE (10/1/2026)Accenture (10/1/2026)PepsiCo (10/8/2026)Delta Air Lines (10/9/2026)America Movil (10/13/2026)BlackRock (10/13/2026)Citigroup (10/13/2026)The Goldman Sachs Group (10/13/2026)JPMorgan Chase & Co. (10/13/2026) Unlock superior investment research and tools. Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools and reports. Get MarketBeat All Access MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In Email Me a Login Link or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
